The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .
A. Sandler
No relevant relationships to disclose
J. H. Schiller
Consultant or Advisory Role - Daiichi Sankyo
V. Hirsh
No relevant relationships to disclose
L. V. Sequist
Consultant or Advisory Role - ArQule (U)
J. Soria
No relevant relationships to disclose
J. Von Pawel
Consultant or Advisory Role - Daiichi Sankyo
Q. Wang
Employment or Leadership Position - Daiichi Sankyo
A. U. Pande
Employment or Leadership Position - Daiichi Sankyo
B. E. Schwartz
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
E. G. Garmey
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
I. Gorbatchevsky
Employment or Leadership Position - Daiichi Sankyo
G. Scagliotti
Honoraria - Roche